Alluvi, formerly BI 4744, represents a significant advance in weight control therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable effectiveness in patient trials, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/